# Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia

> **NCT03651102** · PHASE2,PHASE3 · COMPLETED · sponsor: **Blood Diseases Clinic** · enrollment: 654 (actual)

## Conditions studied

- Thalassemia

## Interventions

- **DRUG:** Thalidomide and Hydroxyurea

## Key facts

- **NCT ID:** NCT03651102
- **Lead sponsor:** Blood Diseases Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-03-01
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2022-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03651102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03651102, "Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03651102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*